Should you invest $1,000 in Vanguard Ftse Canadian High Dividend Yield Index Etf right now?

Before you buy stock in Vanguard Ftse Canadian High Dividend Yield Index Etf, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Vanguard Ftse Canadian High Dividend Yield Index Etf wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $21,058.57!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 38 percentage points since 2013*.

See the Top Stocks * Returns as of 2/20/25

Could Valeant Pharmaceuticals Intl Inc. Be the Rebound Stock of the Year?

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is a hot business with promising revenue drivers in the new year. With the tailwinds behind it, will the stock be one of the biggest winners of 2018?

| More on:
The Motley Fool

Last year, I mentioned that Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) was a high-risk/high-reward stock for those who had the patience to ride the rebound, which I felt was inevitable given the tremendous job that CEO Joseph Papa has done since taking the helm well over a year ago. Now that there’s a foundation in place for organic growth and its debt is down to more manageable levels, I think Valeant is no longer an extremely risky, speculative play. Instead, I think it’s a solid long-term investment whose risk profile is suitable given the potential rewards.

How long will it take to repair Valeant’s damaged reputation?

Despite Papa exceeding expectations with Valeant’s turnaround plan, many investors still may not have forgiven Valeant for its price gouging and shady accounting practices exhibited during its downfall.

That’s understandable, as Pearson’s debt-fuelled, short-term M&A spree destroyed a ton of wealth, and sadly, original investors probably won’t see a complete rebound over the course of the next decade. However, I still believe there’s a great deal of upside that could be enjoyed by patient investors who are willing to focus on the road ahead.

Ultimately, it’ll be the earnings that will dictate the movement of Valeant’s shares. Given Papa’s debt reduction and earnings growth efforts, I think shares could be poised for a pop, which would see investors begin to forget the old Valeant and instead consider the new Valeant as a solid long-term holding.

Papa’s performance thus far

Valeant has reduced its total debt by a whopping $6.5 billion since the end of Q1 2016, much higher than the original ~$5 billion repayment guidance. The larger-than-expected debt repayment was thanks to the divestment of 13 assets, most of which sold for above or around their fair value. In addition, the company eliminated all long-term debt maturities until 2020, which gave Valeant more than enough time to focus on organic growth initiatives rather than cutting deeper into the company’s remaining assets.

Valeant’s wonderful eye health business, Bausch + Lomb, is still around and it’s firing on all cylinders. Going forward, it’ll be a major earnings growth driver for Valeant as it picks up momentum from the newly launched FDA-approved Vyzulta, which could make a huge splash this year. Bausch + Lomb and Valeant’s GI business account for a whopping ~77% of revenues as of Q3, so if Vyzulta ends up becoming a blockbuster drug, Valeant’s shares will surely soar into the stratosphere as investors forget about Valeant’s troubled past and look to its potentially brighter future.

A quick snapshot of what to expect in 2018

Vyzulta and Siliq are too hot drugs that could cause Valeant’s organic revenue to soar. When it comes to Bausch + Lomb, GI and Dermatology are all showing signs of promise in the new year.

Not all is peachy, however, as Valeant’s diversified segment is showing weakness due to the number of generic drugs in its portfolio that are susceptible to various competitors. I don’t believe this is anything to worry about, however, especially since the segment will become more insignificant versus Valeant’s higher-flying businesses.

Currently, the diversified segment accounts for ~15% of revenues, but I suspect that will eventually drop into the single digits, especially considering the momentum enjoyed by Bausch + Lomb.

Bottom line

As far as I’m concerned, its risk profile has decreased significantly during Papa’s tenure. He’s done an impeccable job of cutting down the debt without sabotaging core assets, which will fuel forward growth. Despite exceeding expectations in the debt reduction department, Valeant is still not out of the woods, especially if sales of Vyzulta and Siliq underwhelm in the coming year.

Despite impressive debt repayments, Valeant’s 4.92 debt-to-equity ratio is still on the high side, but given the company’s potential for organic revenue growth, I don’t think investors should be as wary anymore.

At these levels, Valeant is certainly making a strong case for why it could be one of the biggest rebound stories of the year. However, it’ll really depend on the performance of its new hit drugs, Vyzulta and Siliq. They’ve shown promise up till now, but betting on the success of new drugs always comes with a high degree of uncertainty. Given Valeant’s recent near-term surge, I’d recommend buying a very small position today, with the intention of accumulating a larger position on a dip.

Stay hungry. Stay Foolish.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette has no position in any of the stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Utility, wind power
Dividend Stocks

Got 500? 1 Green Energy Stock to Buy and Hold Forever

A TSX green stock is a compelling investment option for long-term, socially conscious investors.

Read more »

Piggy bank and Canadian coins
Dividend Stocks

How to Use Your TFSA to Earn $128 Per Month in Tax-Free Income

These TSX dividend stocks offer high yields and monthly payouts. These stocks can help you earn over $128 in tax-free…

Read more »

Person uses a tablet in a blurred warehouse as background
Tech Stocks

Bargain Alert: 2 AI Champions to Scoop Up During This Market Dip

Canadian investors could consider owning beaten-down AI stocks such as AMD to generate outsized gains in the next 12 months.

Read more »

protect, safe, trust
Stock Market

Stock Market Correction: 3 Safe-Haven Stocks to Own Right Now

If you're looking for stability in these volatile times, then these three stocks might be up your alley.

Read more »

Piggy bank in autumn leaves
Stock Market

TFSA: Savvy Ways to Invest Your 2025 Contribution

Are you wondering what to do with your TFSA right now? Here are some tips on how to invest your…

Read more »

rising arrow with flames
Tech Stocks

Buy the Dip: This Beaten-Down Canadian Stock Could Double From Here

BlackBerry stock has moved beyond smartphones, yet it looks better than ever at these prices.

Read more »

Confused person shrugging
Dividend Stocks

Down 27% From All-Time Highs, Is Brookfield Infrastructure a Buy Right Now?

Down almost 30% from all-time highs, Brookfield Infrastructure is a TSX dividend stock that should deliver outsized gains to shareholders.

Read more »

ways to boost income
Dividend Stocks

TSX Stocks Down Big: Which Ones Are Worth Buying Today?

While this TSX stock may have taken a plunge, it doesn't seem to be from anything the company has done…

Read more »